LEO Pharma announces annual results 2022
9.3.2023 09:30:00 CET | LEO Pharma | Press release
Today, LEO Pharma released its financial results for 2022.
Financial highlights
- Revenue grew 7% vs. last year to 10,641 mDKK. The revenue growth in constant currency rates was 4% and in-line with guidance of 3-5%.
- Growth was driven by 8% growth in the Dermatology portfolio in constant currency rates. Growth was partly off-set by 4% decline in the Thrombosis business and reduced revenue from contract manufacturing of divested products.
- Since 2020 there has been a steady, organic acceleration of the Dermatology growth from 0% in 2020 to 4% in 2021 to 8% in 2022 in constant currency rates. The 8% growth in the Dermatology portfolio was mainly driven by the launch of AdbryTM in the U.S. and continued launch of Adtralza® in EU. In addition, we see solid growth for the established portfolio.
- Adjusted EBITDA loss was 1,253 mDKK, which represents an improvement of 478 mDKK vs. last year because of the revenue growth and lower costs driven by the transformation and restructuring program executed during 2021 and 2022.
- EBIT for 2022 amounted to a loss of 3,311 mDKK and is in line with the guidance of an operating loss (EBIT) of 3.1-3.3 bDKK.
CEO of LEO Pharma, Christophe Bourdon comments:
"We are progressing on our financial turnaround. 2022 was a year characterized by growth in our dermatology portfolio across markets and progress in our pipeline. In 2023, we are laser-focused on delivering positive EBITDA. I would like to thank all my colleagues for getting us to this turning point for the company."
Executing on growth strategy
In 2022, LEO Pharma continued its transformation, preparing to become more profitable and delivering positive EBITDA in 2023. A new commercial model was introduced at the start of the year with the purpose to simplify market operations and ensure full focus on the launch of Adtralza®/Adbry™ across markets. By the end of the year, the treatment was available to patients in 13 markets, including major markets such as the U.S., Spain, Germany, UK and France.
Strengthening the Global Leadership Team
In April, Christophe Bourdon took the reins as CEO. Brian Hilberdink joined as EVP Region North America, Sven Hauptmann as EVP Technical Development and Supply and Philip Eickhoff as CFO and EVP Global Finance and Business Services. The Global Leadership Team now has significant international industry competencies, setting LEO Pharma up to achieve the ambitions of growth and executing on a financial turnaround.
Advancements in R&D pipeline
LEO Pharma’s R&D pipeline progressed significantly in 2022 and achieved important milestones to support future growth. These include:
- Approval of Adtralza® in Japan
- Positive Phase 3 data for DELTA1 trial for delgocitinib, a topical pan-JAK inhibitor for treatment of chronic hand eczema, meeting primary and all key secondary endpoints.
- Positive Phase 2 data for Anti IL-22R, an anti-inflammatory monoclonal antibody for atopic dermatitis, progressing to Phase 2B.
These assets are all outcomes of strategic partnerships. This underpins the recent adjustment of the R&D strategy to have an increased emphasis on external innovation and partnerships.
On track towards sustainability targets
Progress was made towards the targets set out in the sustainability strategy.
The targets to reduce our carbon emissions from own operations by more than 50% from 2019 to 2030 and to ensure that 75% of our suppliers by emissions have set science-based targets by 2026, were validated by the Science Based Target initiative.
Outlook 2023
In 2023, LEO Pharma will continue its focus on delivering positive EBITDA, which is a first and necessary step to driving profitable and sustained growth towards 2025 and beyond. To deliver on the expectations, we anticipate revenue growth of 6-10% in 2023, driven by increasing sale of Adtralza®/Adbry™and growth in the strategic brands. We expect to deliver a low single-digit positive EBITDA margin. Taking the ordinary depreciation and amortization into account, this is expected to result in an operating loss (EBIT) in 2023.
Key figures
|
DKK million |
2022 |
2021 |
Delta |
|
Revenue |
10,641 |
9,967 |
7% |
|
Adjusted EBITDA |
(1,253) |
(1,731) |
28% |
|
EBITDA |
(1,574) |
(1,957) |
20% |
|
Operating profit (EBIT) |
(3,311) |
(4,156) |
20% |
|
Net profit |
(4,110) |
(4,868) |
16% |
|
|
Annual Report 2022
The full results are available in the LEO Pharma Annual Report 2022 on the company’s website at: www.leo-pharma.com
Changes to LEO Pharma’s Board of Directors
At LEO Pharma’s Annual General Meeting 2023 Jesper Mailind stepped down as Vice Chair of the Board of Directors, while continuing as Board member. Board member Paul Navarre was elected new Vice Chair.
- ENDS -
Contacts
Media contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse
Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse
New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.
LEO Pharma receives positive CHMP opinion recommending Anzupgo® (delgocitinib) cream for adolescents with moderate to severe chronic hand eczema in the EU18.9.2026 10:00:00 CEST | Pressemeddelelse
The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate. If approved by the European Commission, Anzupgo® would become the first therapy in the EU specifically approved for adolescents with moderate to severe chronic hand eczema, a patient population for whom there are currently no specifically approved treatment options. The positive CHMP opinion is supported by results from DELTA TEEN, a phase 3 trial investigating the efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema.1
LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma18.9.2026 09:00:00 CEST | Pressemeddelelse
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) date expected by the end of February 2027. LEO Pharma has successfully closed the acquisition of dersimelagon from Tanabe Pharma, strengthening its late-stage pipeline and further leveraging its global dermatology platform. Dersimelagon is an investigational, once-daily oral melanocortin 1 receptor (MC1R) agonist for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), two rare genetic skin diseases with significant unmet medical need.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom